(Q37454341)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

review article

2 references

25 September 2020

Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

1 reference

25 September 2020

1 reference

25 September 2020

1 reference

25 September 2020

alkylating antineoplastic agent

1 reference

25 September 2020

0 references

Georgios V Koukourakis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Vassilios Kouloulias

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Georgios Zacharias

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Christos Papadimitriou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Panagiotis Pantelakos

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

George Maravelis

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Andreas Fotineas

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Ivelina Beli

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Demetrios Chaldeopoulos

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

John Kouvaris

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

language of work or name

English

0 references

publication date

16 April 2009

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

25 September 2020

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

25 September 2020

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

1561-1577

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

26 January 2020

copyright license

1 reference

25 September 2020

0 references

Temozolomide: a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours.

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

The Charing Cross Hospital experience with temozolomide in patients with gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Neck dissection: past, present, future

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Chemotherapy in the treatment of recurrent glioblastoma multiforme: ifosfamide versus temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Importance of the DNA repair enzyme O6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

O6-alkylguanine-DNA-alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Antitumour imidazotetrazines--XI: Effect of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one [CCRG 81045; M and B 39831 NSC 362856] on poly(ADP-ribose) metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Expression of human O6-methylguanine-DNA methyltransferase in Chinese hamster ovary cells and restoration of cellular resistance to certain N-nitroso compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Antitumour imidazotetrazines XXVIII 3-methyladenine DNA glycosylase activity in cell lines sensitive and resistant to temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Biopsy versus resection for malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

The management of brain edema in brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

(ADP-ribose)n participates in DNA excision repair

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FMOLECULES14041561

Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors

21 January 2018

1 reference

12 December 2020

Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds

1 reference

12 December 2020

Triazene compounds induce apoptosis in O6-alkylguanine-DNA alkyltransferase deficient leukemia cell lines

1 reference

12 December 2020

The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy

1 reference

12 December 2020

In vitro and in vivo methazolastone-induced DNA damage and repair in L-1210 leukemia sensitive and resistant to chloroethylnitrosoureas.

1 reference

12 December 2020

Chemosensitivity to triazene compounds and O6-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients

1 reference

12 December 2020

Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.

1 reference

12 December 2020

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine

1 reference

12 December 2020

Phase I study of temozolomide in children and adolescents with recurrent solid tumors: a report from the Children's Cancer Group

1 reference

12 December 2020

Repair of DNA containing O6-alkylguanine

1 reference

12 December 2020

Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma

1 reference

12 December 2020

Phase I trial of temozolomide using an extended continuous oral schedule.

1 reference

12 December 2020

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

12 December 2020

p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells

1 reference

12 December 2020

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

12 December 2020

Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea.

1 reference

12 December 2020

Structure, function, and inhibition of O6-alkylguanine-DNA alkyltransferase.

1 reference

12 December 2020

Chemotherapy for high-grade glioma

1 reference

12 December 2020

In vitro evaluation of temozolomide combined with X-irradiation

1 reference

12 December 2020

Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents

1 reference

12 December 2020

Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin.

1 reference

12 December 2020

Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial

1 reference

12 December 2020

Cytotoxic effects of dacarbazine in patients with acute myelogenous leukemia: a pilot study

1 reference

12 December 2020

10.3390/MOLECULES14041561

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19384285%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference